Compare Natera Inc. Common Stock (NTRA) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Wendys Co — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Wendys Co trades at $6.44 (market cap $1.21B). The key difference: Natera Inc. Common Stock is far larger — about 47.1× Wendys Co's market cap, and Wendys Co pays a 4.41% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Wendys Co for 78 Days on average.
| NTRA | WEN | |
|---|---|---|
Market Cap | $57.03B | $1.21B |
Volume | 1,131,157 | 3,737,069 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $9.33 |
52-Week Low | $179.42 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $56.18B | $4.94B |
Dividend Yield | — | 4.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Wendy's stock trades at $6.44, up 2.06% today, but remains near multi-year lows amid ongoing operational challenges. The company shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, while maintaining consistent revenue around $2.2B. However, declining net income margins (5.72% in 2025) and a major franchisee bankruptcy highlight significant headwinds. Technical indicators show bearish momentum with the stock trading near key support levels.
While Wendy's valuation appears compelling, the stock faces substantial risks from declining profitability, high debt levels, and competitive pressures. Analyst consensus leans cautious with a $7.58 price target, suggesting limited upside. The recent CEO change and international expansion plans offer potential catalysts, but execution risks remain elevated given the challenging restaurant environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
